Q32 Bio Stock Boosts on Strategic Asset Sale

Q32 Bio shares are trading higher after the company sold its complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront and potential payments up to $592 million, strengthening its cash position.